Phase II Pilot of Aromatase Inhibitor Therapy With Femara (Letrozole) and Ovarian Suppression in Premenopausal Estrogen Receptor Positive Women With Stage IV Carcinoma of the Breast.

Trial Profile

Phase II Pilot of Aromatase Inhibitor Therapy With Femara (Letrozole) and Ovarian Suppression in Premenopausal Estrogen Receptor Positive Women With Stage IV Carcinoma of the Breast.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 May 2013

At a glance

  • Drugs Letrozole (Primary) ; Goserelin; Leuprorelin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2012 Actual patient number is 1 according to ClinicalTrials.gov.
    • 01 Oct 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top